Kinetics of Response to First‐ and Second‐Line Therapies in Multiple Myeloma‐ Assessment by Both M‐spikes and Light Chains

2021 ◽  
Author(s):  
Eyal Lebel ◽  
Xuan Li ◽  
Harminder Paul ◽  
Esther Masih‐Khan ◽  
Sita Bhella ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Light Chains ◽  
Second Line ◽  
Kinetics Of

scholarly journals T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma

1999 ◽  
Vol 80 (5) ◽  
pp. 671-680 ◽  
Author(s):  
Jan Fagerberg ◽  
Qing Yi ◽  
Dulceaydee Gigliotti ◽  
Ulrika Harmenberg ◽  
Ulla Rud�n ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Cell ◽  
Epitope Mapping ◽  
Cell Epitope ◽  
Light Chains ◽  
T Cell Epitope

Factors associated with second-line triplet therapy in routine care in relapsed/refractory multiple myeloma

2017 ◽  
Vol 43 (1) ◽  
pp. 45-51 ◽  
Author(s):  
P. Hari ◽  
D. Romanus ◽  
H. J. Henk ◽  
L. K. Becker ◽  
S. J. Noga ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Routine Care ◽  
Second Line ◽  
Refractory Multiple Myeloma ◽  
Factors Associated

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)

Blood ◽  
2005 ◽  
Vol 105 (7) ◽  
pp. 2949-2951 ◽  
Author(s):  
Giovanni Palladini ◽  
Vittorio Perfetti ◽  
Stefano Perlini ◽  
Laura Obici ◽  
Francesca Lavatelli ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cells ◽  
Primary Amyloidosis ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Symptomatic Bradycardia ◽  
Intermediate Dose

AbstractBased on the efficacy of thalidomide in multiple myeloma and on its synergy with dexamethasone on myeloma plasma cells, we evaluated the combination of thalidomide (100 mg/d, with 100-mg increments every 2 weeks, up to 400 mg) and dexamethasone (20 mg on days 1-4) every 21 days in 31 patients with primary amyloidosis (AL) whose disease was refractory to or had relapsed after first-line therapy. Eleven (35%) patients tolerated the 400 mg/d thalidomide dose. Overall, 15 (48%) patients achieved hematologic response, with 6 (19%) complete remissions and 8 (26%) organ responses. Median time to response was 3.6 months (range, 2.5-8.0 months). Treatment-related toxicity was frequent (65%), and symptomatic bradycardia was a common (26%) adverse reaction. The combination of thalidomide and dexamethasone is rapidly effective and may represent a valuable second-line treatment for AL.

scholarly journals Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma

2018 ◽  
Vol 7 (6) ◽  
pp. 2256-2268
Author(s):  
Johan Lund ◽  
Astrid Gruber ◽  
Birgitta Lauri ◽  
Adil Doganay Duru ◽  
Cecilie Blimark ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Prolonged Treatment ◽  
Second Line
Sign in / Sign up

Export Citation Format

Share Document